The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.
The CCL5/CCR5 Axis in Cancer Progression
Open accessAbstract
Tumor cells can “hijack” chemokine networks to support tumor progression. In this context, the C-C chemokine ligand 5/C-C chemokine receptor type 5 (CCL5/CCR5) axis is gaining increasing attention, since abnormal expression and activity of CCL5 and its receptor CCR5 have been found in hematological malignancies and solid tumors. Numerous preclinical in vitro and in vivo studies have shown a key role of the CCL5/CCR5 axis in cancer, and thus provided the rationale for clinical trials using the repurposed drug maraviroc, a CCR5 antagonist used to treat HIV/AIDS. This review summarizes current knowledge on the role of the CCL5/CCR5 axis in cancer. First, it describes the involvement of the CCL5/CCR5 axis in cancer progression, including autocrine and paracrine tumor growth, ECM (extracellular matrix) remodeling and migration, cancer stem cell expansion, DNA damage repair, metabolic reprogramming, and angiogenesis. Then, it focuses on individual hematological and solid tumors in which CCL5 and CCR5 have been studied preclinically. Finally, it discusses clinical trials of strategies to counteract the CCL5/CCR5 axis in different cancers using maraviroc or therapeutic monoclonal antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Migration: Integrating Signals from Front to Back
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., & Horwitz, A. R. (2003) · Science · doi:10.1126/science.1092053 · Cited by 4,978
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 6×
“Macrophages secrete molecules that induce EMT and enhance the invasiveness of mutated cancer cells.”
BackgroundInfluentialTumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,118
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Metabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
(1997) · PubMed · Cited by 1,541
Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912
Dangaj, D., Bruand, M., Grimm, A. J., Ronet, C., Barras, D., Duttagupta, P. A., Lanitis, E., Duraiswamy, J., Tanyi, J. L., Benencia, F., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.004 · Cited by 875
MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death
Schickel, R., Boyerinas, B., Park, S.-M., & Peter, M. E. (2008) · Oncogene · doi:10.1038/onc.2008.274 · Cited by 719
Role of platelets and platelet receptors in cancer metastasis
Schlesinger, M. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0669-2 · Cited by 690
RANTES: a versatile and controversial chemokine
Appay, V., & Rowland-Jones, S. L. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(00)01812-3 · Cited by 650
The Platelet Lifeline to Cancer: Challenges and Opportunities
Haemmerle, M., Stone, R. L., Menter, D. G., Afshar-Kharghan, V., & Sood, A. K. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.002 · Cited by 638
The inflammatory chemokines CCL2 and CCL5 in breast cancer
Soria, G., & Ben-Baruch, A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.018 · Cited by 593
A peek into cancer-associated fibroblasts: origins, functions and translational impact
LeBleu, V. S., & Kalluri, R. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.029447 · Cited by 537
Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
Teleanu, R. I., Chircov, C., Grumezescu, A. M., & Teleanu, D. M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010084 · Cited by 503
Halama, N., Zoernig, I., Berthel, A., Kahlert, C., Klupp, F., Suarez-Carmona, M., Suetterlin, T., Brand, K., Krauss, J., Lasitschka, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.005 · Cited by 495
Cancer-associated adipocytes: key players in breast cancer progression
Wu, Q., Li, B., Li, Z., Li, J., Sun, S., & Sun, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0778-6 · Cited by 462 · cited 1×
“By secreting chemokines, cancer cells recruit T cells, monocytes, myeloid cells, fibroblasts and mesenchymal stromal cells (MSCs) from bone marrow or adipose tissue, and then “educate” [3] them to become immunosuppressive T regulatory cells (Tregs) [4], tumor-associated macrophages (M2-TAM) [5], myeloid-derived suppre…”
BackgroundThe Inflammatory Chemokine CCL5 and Cancer Progression
Aldinucci, D., & Colombatti, A. (2014) · Mediators of Inflammation · doi:10.1155/2014/292376 · Cited by 438
Self-citationSchlecker, E., Stojanovic, A., Eisen, C., Quack, C., Falk, C. S., Umansky, V., & Cerwenka, A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201018 · Cited by 438
Daly, A. F., Tichomirowa, M. A., Petrossians, P., Heliövaara, E., Jaffrain-Rea, M.-L., Barlier, A., Naves, L. A., Ebeling, T., Karhu, A., Raappana, A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2556 · Cited by 384
Chemokine receptor CCR5: insights into structure, function, and regulation
Oppermann, M. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.04.007 · Cited by 376
MicroRNAs Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts in Ovarian Cancer
Mitra, A. K., Zillhardt, M., Hua, Y., Tiwari, P., Murmann, A. E., Peter, M. E., & Lengyel, E. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0206 · Cited by 371
Luboshits, G., Shina, S., Kaplan, O., Engelberg, S., Nass, D., Lifshitz-Mercer, B., Chaitchik, S., Keydar, I., & Ben‐Baruch, A. (1999) · PubMed · Cited by 350
Abe, M., Hiura, K., Wilde, J., Shioyasono, A., Moriyama, K., Hashimoto, T., Kido, S., Oshima, T., Shibata, H., Ozaki, S., et al. (2004) · Blood · doi:10.1182/blood-2003-11-3839 · Cited by 318
Abe, M., Hiura, K., Wilde, J., Moriyama, K., Hashimoto, T., Ozaki, S., Wakatsuki, S., Kosaka, M., Kido, S., Inoue, D., et al. (2002) · Blood · doi:10.1182/blood.v100.6.2195 · Cited by 294
Chemotherapy Resistance in Advanced Ovarian Cancer Patients
Pokhriyal, R., Hariprasad, R., Kumar, L., & Hariprasad, G. (2019) · Biomarkers in Cancer · doi:10.1177/1179299x19860815 · Cited by 283
CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells
Velasco-Velázquez, M., Jiao, X., De La Fuente, M., Pestell, T. G., Ertel, A., Lisanti, M. P., & Pestell, R. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3917 · Cited by 282
Aldinucci, D., Gloghini, A., Pinto, A., De Filippi, R., & Carbone, A. (2010) · The Journal of Pathology · doi:10.1002/path.2711 · Cited by 275
Self-citationAntitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
Germano, G., Frapolli, R., Simone, M., Tavecchio, M., Erba, E., Pesce, S., Pasqualini, F., Grosso, F., Sanfilippo, R., Casali, P. G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2335 · Cited by 267
Huang, R., Wang, S., Wang, N., Zheng, Y., Zhou, J., Yang, B., Wang, X., Zhang, J., Guo, L., Wang, S., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2435-y · Cited by 263
Do, H. T. T., Lee, C. H., & Cho, J. (2020) · Cancers · doi:10.3390/cancers12020287 · Cited by 234
Chang, L.-Y., Lin, Y.-C., Mahalingam, J., Huang, C.-T., Chen, T.-W., Kang, C.-W., Peng, H.-M., Chu, Y.-Y., Chiang, J.-M., Dutta, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2493 · Cited by 232
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology
Jiao, X., Nawab, O., Patel, T., Kossenkov, A. V., Halama, N., Jaeger, D., & Pestell, R. G. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1167 · Cited by 232
Expression of CCL5 (RANTES) and CCR5 in prostate cancer
Vaday, G. G., Peehl, D. M., Kadam, P. A., & Lawrence, D. M. (2006) · The Prostate · doi:10.1002/pros.20306 · Cited by 230
Barcellos-de-Souza, P., Comito, G., Pons-Segura, C., Taddei, M. L., Gori, V., Becherucci, V., Bambi, F., Margheri, F., Laurenzana, A., Del Rosso, M., et al. (2016) · Stem Cells · doi:10.1002/stem.2412 · Cited by 230
Liu, C., Yao, Z., Wang, J., Zhang, W., Yang, Y., Zhang, Y., Qu, X., Zhu, Y., Zou, J., Peng, S., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0460-0 · Cited by 230
Lentzsch, S., Gries, M., Janz, M., Bargou, R., Dörken, B., & Mapara, M. Y. (2003) · Blood · doi:10.1182/blood-2002-08-2383 · Cited by 218
Bose, S., & Le, A. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-77736-8_1 · Cited by 212
CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors
Walens, A., DiMarco, A. V., Lupo, R., Kroger, B. R., Damrauer, J. S., & Alvarez, J. V. (2019) · eLife · doi:10.7554/elife.43653 · Cited by 205
Long, H., Xie, R., Xiang, T., Zhao, Z., Lin, S., Liang, Z., Chen, Z., & Zhu, B. (2012) · STEM CELLS · doi:10.1002/stem.1194 · Cited by 202
Lee, E., Fertig, E. J., Jin, K., Sukumar, S., Pandey, N. B., & Popel, A. S. (2014) · Nature Communications · doi:10.1038/ncomms5715 · Cited by 197 · cited 1×
“Cross-talk between triple-negative breast cancer cells and stromal lymphatic endothelial cells (LECs) is involved in tumor growth and metastasis [154].”
BackgroundBinder, S., Luciano, M., & Horejs-Hoeck, J. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.08.004 · Cited by 190
CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions
Blattner, C., Fleming, V., Weber, R., Himmelhan, B., Altevogt, P., Gebhardt, C., Schulze, T. J., Razon, H., Hawila, E., Wildbaum, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0348 · Cited by 182
Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis
Mi, Z., Bhattacharya, S. D., Kim, V. M., Guo, H., Talbot, L. J., & Kuo, P. C. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr009 · Cited by 179
CCL5 increases lung cancer migration via PI3K, Akt and NF-κB pathways
Huang, C.-Y., Fong, Y.-C., Lee, C.-Y., Chen, M.-Y., Tsai, H.-C., Hsu, H.-C., & Tang, C.-H. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.014 · Cited by 176
Chemokines and Chemokine Receptors: Orchestrating Tumor Metastasization
Marcuzzi, E., Angioni, R., Molon, B., & Calì, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010096 · Cited by 173
Glucose Metabolism on Tumor Plasticity, Diagnosis, and Treatment
Lin, X., Xiao, Z., Chen, T., Liang, S. H., & Guo, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00317 · Cited by 173
Nie, Y., Huang, H., Guo, M., Chen, J., Wu, W., Li, W., Xu, X., Lin, X., Fu, W., Yao, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3421 · Cited by 168
Terpos, E., Politou, M., Szydlo, R., Goldman, J. M., Apperley, J. F., & Rahemtulla, A. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04561.x · Cited by 167
Ban, Y., Mai, J., Li, X., Mitchell-Flack, M., Zhang, T., Zhang, L., Chouchane, L., Ferrari, M., Shen, H., & Ma, X. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2913 · Cited by 166
Tumour-associated macrophages and cancer
Cook, J., & Hagemann, T. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.05.017 · Cited by 165
CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells
Singh, S. K., Mishra, M. K., Eltoum, I.-E. A., Bae, S., Lillard, J. W., & Singh, R. (2018) · Scientific Reports · doi:10.1038/s41598-018-19643-0 · Cited by 165
Zhang, X., Chen, L., Dang, W.-Q., Cao, M.-F., Xiao, J.-F., Lv, S.-Q., Jiang, W.-J., Yao, X.-H., Lu, H.-M., Miao, J.-Y., et al. (2020) · Laboratory Investigation · doi:10.1038/s41374-019-0345-3 · Cited by 163
Luo, J., Lee, S., Liang, L., Huang, C.-K., Li, L., Wen, S., & Chang, C. (2013) · Oncogene · doi:10.1038/onc.2013.233 · Cited by 162
Vallet, S., Pozzi, S., Patel, K. J., Vaghela, N. N., Fulciniti, M., Veiby, P. O., Hideshima, T., Santo, L., Cirstea, D. D., Scadden, D. T., et al. (2011) · Leukemia · doi:10.1038/leu.2011.43 · Cited by 160
Selective infiltration of CCR5 + CXCR3 + T lymphocytes in human colorectal carcinoma
Musha, H., Ohtani, H., Mizoi, T., Kinouchi, M., Nakayama, T., Shiiba, K., 宮川, 菊., Nagura, H., Yoshie, O., & Sasaki, I. (2005) · International Journal of Cancer · doi:10.1002/ijc.21135 · Cited by 159
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues
Maggio, E. M., van den Berg, A., Diepstra, A., Kluiver, J. L., Visser, L., & Poppema, S. (2002) · Annals of Oncology · doi:10.1093/annonc/13.s1.52 · Cited by 157
Zucchetto, A., Benedetti, D., Tripodo, C., Bomben, R., Bo, M. D., Marconi, D., Bossi, F., Lorenzon, D., Degan, M., Rossi, F. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4173 · Cited by 156
Wang, S., Liu, S., Sun, H., Huang, T., Chan, C.-H., Yang, C., Yeh, H., Huang, Y., Chou, W., Lin, Y., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu218 · Cited by 156
Oba, Y., Lee, J., Ehrlich, L. A., Chung, H. Y., Jelinek, D. F., Callander, N. S., Horuk, R., Choi, S. J., & Roodman, G. D. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.11.015 · Cited by 156
Aldinucci, D., Lorenzon, D., Cattaruzza, L., Pinto, A., Gloghini, A., Carbone, A., & Colombatti, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.23119 · Cited by 152
Self-citationInhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer
Aldinucci, D., & Casagrande, N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051477 · Cited by 150
Self-citationCambien, B., Richard, P., Karimdjee-Soilihi, B., Martini, V., Ferruà, B., Pitard, B., Schmid‐Antomarchi, H., & Schmid‐Alliana, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028842 · Cited by 138
Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment
Атретханы, К.-С. Н., Drutskaya, M. S., Nedospasov, S. A., Grivennikov, S. I., & Kuprash, D. V. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.011 · Cited by 138
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
Jiao, X., Velasco-Velázquez, M. A., Wang, M., Li, Z., Rui, H., Peck, A. R., Korkola, J. E., Chen, X., Xu, S., DuHadaway, J. B., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0915 · Cited by 138
Bruserud, Ø., Ryningen, A., Olsnes, A. M., Stordrange, L., Oyan, A. M., Kalland, K. H., & Gjertsen, B. T. (2007) · Haematologica · doi:10.3324/haematol.10148 · Cited by 137
Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites.
Milliken, D., Scotton, C. J., Raju, S., Balkwill, F. R., & Wilson, J. L. (2002) · PubMed · Cited by 136
Fischer, M., Juremalm, M., Olsson, N., Backlin, C., Sundström, C., Nilsson, K., Enblad, G., & Nilsson, G. P. (2003) · International Journal of Cancer · doi:10.1002/ijc.11370 · Cited by 135
CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity
Huffman, A. P., Lin, J. H., Kim, S. I., Byrne, K. T., & Vonderheide, R. H. (2020) · JCI Insight · doi:10.1172/jci.insight.137263 · Cited by 135
CCL5 derived from platelets increases megakaryocyte proplatelet formation
Machlus, K. R., Johnson, K. E., Kulenthirarajan, R., Forward, J. A., Tippy, M. D., Soussou, T. S., El-Husayni, S. H., Wu, S., Wang, S., Watnick, R. S., et al. (2015) · Blood · doi:10.1182/blood-2015-05-644583 · Cited by 133
Zhang, Y., Lv, D., Kim, H.-J., Kurt, R. A., Bu, W., Li, Y., & Ma, X. (2012) · Cell Research · doi:10.1038/cr.2012.178 · Cited by 129
Colombatti, M., Grasso, S., Porzia, A., Fracasso, G., Scupoli, M. T., Cingarlini, S., Poffe, O., Naim, H. Y., Heine, M., Tridente, G., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004608 · Cited by 127
Agere, S. A., Akhtar, N., Watson, J. M., & Ahmed, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01341 · Cited by 127
Roscic, B., Fischer, M., Leemann, C., Manrique, A., Gordon, C. J., Moore, J. P., Proudfoot, A. E. I., & Trkola, A. (2003) · Blood · doi:10.1182/blood-2003-02-0488 · Cited by 124
Clinical significance of chemokine receptor antagonists
Miao, M., Clercq, E. D., & Li, G. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1711884 · Cited by 124
Menu, E., Leenheer, E. D., Raeve, H. D., Coulton, L. A., Imanishi, T., Miyashita, K., Valckenborgh, E. V., Riet, I. V., Camp, B. V., Horuk, R., et al. (2006) · Clinical & Experimental Metastasis · doi:10.1007/s10585-006-9038-6 · Cited by 122
Liu, C., Yao, Z., Wang, J., Zhang, W., Yang, Y., Zhang, Y., Qu, X., Zhu, Y., Zou, J., Peng, S., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0506-3 · Cited by 122
Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression via CCR5
Nishikawa, G., Kawada, K., Nakagawa, J., Toda, K., Ogawa, R., Inamoto, S., Mizuno, R., Itatani, Y., & Sakai, Y. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1508-2 · Cited by 120
RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans
Suffee, N., Hlawaty, H., Meddahi‐Pellé, A., Maillard, L., Louedec, L., Haddad, O., Martin, L., Laguillier, C., Richard, B., Oudar, O., et al. (2012) · Angiogenesis · doi:10.1007/s10456-012-9285-x · Cited by 119
Aldinucci, D., Celegato, M., & Casagrande, N. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.007 · Cited by 118
Self-citationAnsems, M., & Span, P. N. (2020) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2020.04.001 · Cited by 116
Halvorsen, E. C., Hamilton, M. J., Young, A., Wadsworth, B. J., LePard, N. E., Lee, H. N., Firmino, N. S., Collier, J. L., & Bennewith, K. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1150398 · Cited by 115
Zhou, B., Sun, C., Li, N., Shan, W., Lü, H., Guo, L., Guo, E., Xia, M., WENG, D., Li, M., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3442 · Cited by 114
Solga, A. C., Pong, W. W., Keun-young Kim, A., Cimino, P. J., Toonen, J. A., Walker, J., Wylie, T., Magrini, V. J., Griffith, M., Griffith, O. L., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.10.002 · Cited by 112
Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease
Carbone, A., Gloghini, A., Aldinucci, D., Gattei, V., Dalla‐Favera, R., & Gaïdano, G. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03456.x · Cited by 111
Self-citationCCL5 as a potential immunotherapeutic target in triple-negative breast cancer
Lv, D., Zhang, Y., Kim, H.-J., Zhang, L., & Ma, X. (2013) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.69 · Cited by 107
The Expanding Therapeutic Perspective of CCR5 Blockade
Vangelista, L., & Vento, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01981 · Cited by 107
CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer
Pasquier, J., Gosset, M., Geyl, C., Hoarau-Véchot, J., Chevrot, A., Pocard, M. D., Mirshahi, M., Lis, R., Rafii, A., & Touboul, C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0787-z · Cited by 103
Lin, S., Wan, S., Sun, L., Hu, J., Fang, D., Zhao, R., Yuan, S., & Zhang, L. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02259.x · Cited by 100
Jin, K., Pandey, N. B., & Popel, A. S. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0981-3 · Cited by 99
Long, H., Xiang, T., Qi, W., Huang, J., Chen, J., He, L., Liang, Z., Guo, B., Li, Y., Xie, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3462 · Cited by 98
CCL5 and CCR5 Interaction Promotes Cell Motility in Human Osteosarcoma
Wang, S., Wu, H.-H., Liu, S., Wang, P., Ou, W., Chou, W., Shen, Y., & Tang, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035101 · Cited by 97
CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. S. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1988-9 · Cited by 96
You, Y., Li, Y., Li, M., Lei, M., Wu, M., Qu, Y., Yuan, Y., Chen, T., & Jiang, H. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13044 · Cited by 96
Mesenchymal Stem/Stromal Cells in Stromal Evolution and Cancer Progression
Cammarota, F., & Laukkanen, M. O. (2015) · Stem Cells International · doi:10.1155/2016/4824573 · Cited by 95
Seo, W., Shimizu, K., Kojo, S., Okeke, A., Kohwi-shigematsu, T., Fujii, S., & Taniuchi, I. (2020) · Nature Communications · doi:10.1038/s41467-020-15375-w · Cited by 95
Wang, R., Feng, W., Wang, H., Wang, L., Yang, X. Q., Yang, F., Zhang, Y., Liu, X., Zhang, D., Ren, Q., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.032 · Cited by 94
Kato, T., Fujita, Y., Nakane, K., Mizutani, K., Terazawa, R., Ehara, H., Kanimoto, Y., Kojima, T., Nozawa, Y., Deguchi, T., et al. (2013) · Cytokine · doi:10.1016/j.cyto.2013.06.313 · Cited by 90
Hashimoto, T., Abe, M., Oshima, T., Shibata, H., Ozaki, S., Inoue, D., & Matsumoto, T. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04864.x · Cited by 89
Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors
Barry, S., Carlsen, E., Marques, P., Stiles, C. E., Gadaleta, E., Berney, D. M., Roncaroli, F., Chelala, C., Solomou, A., Herincs, M., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0779-5 · Cited by 89
STAT3-RANTES Autocrine Signaling Is Essential for Tamoxifen Resistance in Human Breast Cancer Cells
Yi, E. H., Lee, C. S., Lee, J., Lee, Y. J., Shin, M. K., Cho, C., Kang, K. W., Lee, S. E., Han, W., Noh, D., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0217 · Cited by 87
CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease
Dairaghi, D. J., Oyajobi, B. O., Gupta, A., McCluskey, B., Miao, S., Powers, J. P., Seitz, L. C., Wang, Y., Zeng, Y., Zhang, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384784 · Cited by 86
Gallo, M., Luca, A. D., Lamura, L., & Normanno, N. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr159 · Cited by 86
Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme
Kranjc, M. K., Novak, M., Pestell, R. G., & Lah, T. T. (2019) · Radiology and Oncology · doi:10.2478/raon-2019-0057 · Cited by 84
Endothelial cells promote metastasis of prostate cancer by enhancing autophagy
Zhao, R., Bei, X., Yang, B., Wang, X., Jiang, C., Shi, F., Wang, X., Zhu, Y., Jing, Y., Han, B., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0884-2 · Cited by 83
Swamydas, M., Ricci, K., Rego, S. L., & Dréau, D. (2013) · Cell Adhesion & Migration · doi:10.4161/cam.25138 · Cited by 82
Sasaki, S., Baba, T., Shinagawa, K., Matsushima, K., & Mukaida, N. (2014) · International Journal of Cancer · doi:10.1002/ijc.28779 · Cited by 80
CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation
Murooka, T. T., Rahbar, R., & Fish, E. N. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.035 · Cited by 78
Ben‐Baruch, A. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0094-3 · Cited by 78
CCL5-deficiency enhances intratumoral infiltration of CD8+ T cells in colorectal cancer
Zhang, S., Zhong, M., Wang, C., Xu, Y., Gao, W., & Zhang, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0796-2 · Cited by 77
Tumor-infiltrating regulatory T cells: origins and features.
Deng, G. (2018) · Europe PMC (PubMed Central) · Cited by 76
Sugasawa, H., Ichikura, T., Kinoshita, M., Ono, S., Majima, T., Tsujimoto, H., Chochi, K., Hiroi, S., Takayama, E., Saitoh, D., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23401 · Cited by 75
Adipocytes in the Tumour Microenvironment
Pallegar, N. K., & Christian, S. L. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-37184-5_1 · Cited by 73
Tang, S., Xiang, T., Huang, S., Zhou, J., Wang, Z., Xie, R., Long, H., & Zhu, B. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.034 · Cited by 71
Alterations of T-cell-mediated immunity in acute myeloid leukemia
Li, Z., Philip, M., & Ferrell, P. B. (2020) · Oncogene · doi:10.1038/s41388-020-1239-y · Cited by 70
Hypoxia and macrophages promote glioblastoma invasion by the CCL4-CCR5 axis
Wang, Y., Liu, T., Yang, N., Xu, S., Li, X., & Wang, D. (2016) · Oncology Reports · doi:10.3892/or.2016.5171 · Cited by 68
CCL5 secreted by tumor associated macrophages may be a new target in treatment of gastric cancer
Ding, H., Zhao, L., Dai, S., Li, L., Wang, F., & Shan, B. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.12.004 · Cited by 67
Yang, X. F., Hou, J., Han, Z., Wang, Y., Hao, C., Wei, L., & Shi, Y. (2013) · Cell & Bioscience · doi:10.1186/2045-3701-3-5 · Cited by 65
Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer
Sugasawa, H., Ichikura, T., Tsujimoto, H., Kinoshita, M., Morita, D., Ono, S., Chochi, K., Tsuda, H., Seki, S., & Mochizuki, H. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.20984 · Cited by 65
Tanabe, Y., Sasaki, S., Mukaida, N., & Baba, T. (2016) · Oncotarget · doi:10.18632/oncotarget.10227 · Cited by 63
Aldinucci, D., Borghese, C., & Casagrande, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102416 · Cited by 63
Self-citationZhong, W., Tong, Y., Li, Y., Yuan, J., Hu, S., Hu, T., & Song, G. (2017) · Oncotarget · doi:10.18632/oncotarget.17793 · Cited by 62
Can we change the disease biology of multiple myeloma?
Borrello, I. (2012) · Leukemia Research · doi:10.1016/s0145-2126(12)70003-6 · Cited by 61
Błaszczyk, J., Coillie, E. V., Proost, P., Damme, J. V., Opdenakker, G., Bujacz, G., Wang, J., & Ji, X. (2000) · Biochemistry · doi:10.1021/bi0009340 · Cited by 61
The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment
Aldinucci, D., Gloghini, A., Pinto, A., Colombatti, A., & Carbone, A. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.605190 · Cited by 60
Self-citationBlockade of CCR5 receptor prevents M2 microglia phenotype in a microglia-glioma paradigm
Laudati, E., Currò, D., Navarra, P., & Lisi, L. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.03.002 · Cited by 60
Tsukishiro, S., Suzumori, N., Nishikawa, H., Arakawa, A., & Suzumori, K. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.01.029 · Cited by 59
EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer
Xia, L., Zhu, X., Zhang, L., Xu, Y., Chen, G., & Luo, J. (2019) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1875 · Cited by 59
Huang, H., Zepp, M., Georges, R. B., Jarahian, M., Kazemi, M., Eyol, E., & Berger, M. R. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.009 · Cited by 59
CCR5 inhibitors: emergence, success, and challenges
Maeda, K., Das, D., Nakata, H., & Mitsuya, H. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.673584 · Cited by 58
The HIV co-receptor CCR5 regulates osteoclast function
Lee, J., Hoshino, A., Inoue, K., Saitou, T., Uehara, S., Kobayashi, Y., Ueha, S., Matsushima, K., Yamaguchi, A., Imai, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02368-5 · Cited by 58
CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination
Mencarelli, A., Graziosi, L., Renga, B., Cipriani, S., D’Amore, C., Francisci, D., Bruno, A. M., Baldelli, F., Donini, A., & Fiorucci, S. (2013) · Translational Oncology · doi:10.1593/tlo.13499 · Cited by 56
Ρούσσου, Μ., Tasidou, A., Dimopoulos, M. A., Kastritis, E., Migkou, M., Christoulas, D., Gavriatopoulou, M., Zagouri, F., Matsouka, C., Anagnostou, D., et al. (2009) · Leukemia · doi:10.1038/leu.2009.130 · Cited by 55
Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling
Xiang, P., Jin, S., Yang, Y., Sheng, J., He, Q., Song, Y., Yu, W., Hu, S., & Jin, J. (2019) · The Prostate · doi:10.1002/pros.23810 · Cited by 55
González‐Arriagada, W. A., Lozano‐Burgos, C., Zúñiga‐Moreta, R., González‐Díaz, P., & Coletta, R. D. (2018) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12736 · Cited by 52
Zhang, X., Haney, K. M., Richardson, A. C., Wilson, E. N., Gewirtz, D. A., Ware, J. L., Zehner, Z. E., & Zhang, Y. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.003 · Cited by 51
CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells
Pervaiz, A., Ansari, S. S., Berger, M. R., & Adwan, H. (2015) · Medical Oncology · doi:10.1007/s12032-015-0607-x · Cited by 51
The orphan G‐protein‐coupled receptor 75 signaling is activated by the chemokine CCL 5
Dedoni, S., Campbell, L. A., Harvey, B. K., Avdoshina, V., & Mocchetti, I. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14463 · Cited by 51
Pan, Y., Smithson, L. J., Ma, Y., Hambardzumyan, D., & Gutmann, D. H. (2017) · Oncotarget · doi:10.18632/oncotarget.16516 · Cited by 50
Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells
Liu, H., Wang, S.-H., Chen, S., Chen, C.-Y., & Lin, T. (2019) · BMC Cancer · doi:10.1186/s12885-019-5379-9 · Cited by 49
CCR5 status and metastatic progression in colorectal cancer
Suarez‐Carmona, M., Chaorentong, P., Kather, J. N., Rothenheber, R., Ahmed, A., Berthel, A., Heinzelmann, A., Moraleda, R. R., Valous, N. A., Koşaloğlu‐Yalçın, Z., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1626193 · Cited by 48
Yang, T., Chen, M., Yang, X., Zhang, X., Zhang, Z., Sun, Y., Xu, B., Hua, J., He, Z., & Song, Z. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1373219 · Cited by 47
Udi, J., Schüler, J. B., Wider, D., Ihorst, G., Catusse, J., Waldschmidt, J. M., Schnerch, D., Follo, M., Wäsch, R., & Engelhardt, M. M. (2013) · British Journal of Haematology · doi:10.1111/bjh.12226 · Cited by 44
Wang, L.-H., Lin, C., Liu, S.-C., Liu, G., Chen, Y., Chen, J., Chan, C.-H., Lin, T.-Y., Chen, C.-K., Xu, G.-H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9213 · Cited by 44
Liu, J., Wang, C., Ma, X., Tian, Y., Wang, C., Fu, Y., & Luo, Y. (2018) · The Journal of Pathology · doi:10.1002/path.5207 · Cited by 44
Luo, J., Lee, S. O., Cui, Y., Yang, R., Li, L., & Chang, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4515 · Cited by 41
CCR1 as a target for multiple myeloma
Vallet, S., & Anderson, K. C. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.586634 · Cited by 41
Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer
Sax, M. J., Gasch, C., Athota, V. R., Freeman, R., Rasighaemi, P., Westcott, D. E., Day, C. J., Nikolić, I., Elsworth, B., Wei, M. Q., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13387 · Cited by 41
Borghese, C., Cattaruzza, L., Pivetta, E., Normanno, N., Luca, A. D., Mazzucato, M., Celegato, M., Colombatti, A., & Aldinucci, D. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24456 · Cited by 39
Self-citationChemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia
Mukaida, N., Tanabe, Y., & Baba, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081824 · Cited by 39
Song, X., Zhou, X., Qin, Y., Yang, J., Wang, Y., Sun, Z., Yu, K., Zhang, S., & Liu, S. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3638 · Cited by 39
Zazo, S., Gónzález-Alonso, P., Martı́n-Aparicio, E., Chamizo, C., Luque, M., Sanz-Álvarez, M., Mínguez, P., Goméz-López, G., Cristóbal, I., Caramés, C., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1172 · Cited by 39
Zucchetto, A., Tripodo, C., Benedetti, D., Deaglio, S., Gaïdano, G., Poeta, G. D., & Gattei, V. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08152.x · Cited by 38
IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion
Aldinucci, D., Celegato, M., Borghese, C., Colombatti, A., & Carbone, A. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08497.x · Cited by 37
Self-citationWang, T., Wei, Y., Tian, L., Song, H., Ma, Y., Yao, Q., Feng, M., Wang, Y., Gao, M., & Xue, Y. (2016) · International Journal of Surgery · doi:10.1016/j.ijsu.2016.07.008 · Cited by 37
The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer
Üçüncü, M., Serilmez, M., Sarı, M., Bademler, S., & Karabulut, S. (2019) · Biomolecules · doi:10.3390/biom9090464 · Cited by 36
CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
Waldeck, S., Rassner, M. P., Keye, P., Follo, M., Herchenbach, D., Endres, C., Charlet, A., Andrieux, G., Salzer, U., Boerries, M., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12640 · Cited by 35
Ovarian Cancer Dissemination—A Cell Biologist’s Perspective
Farsinejad, S., Cattabiani, T., Muranen, T. E., & Iwanicki, M. (2019) · Cancers · doi:10.3390/cancers11121957 · Cited by 34
Chemokines in breast cancer: Regulating metabolism
Gao, D. F., & Fish, E. N. (2018) · Cytokine · doi:10.1016/j.cyto.2018.02.010 · Cited by 31
Autocrine CCL5 promotes tumor progression in esophageal squamous cell carcinoma in vitro
Wu, Y., Shen, Y., Chang, J. W., Hsieh, J., Chu, Y., & Wang, C. (2018) · Cytokine · doi:10.1016/j.cyto.2018.04.027 · Cited by 30
The saponin DT-13 inhibits gastric cancer cell migration through down-regulation of CCR5-CCL5 axis
Lin, S., Fan, W. Q., Sun, L., Li, F., Zhao, R., Zhang, L., Yu, B., & Yuan, S. (2014) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(14)60125-4 · Cited by 28
Sima, A. R., Sima, H. R., Rafatpanah, H., et al. (2014) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-014-9652-5 · Cited by 27
Sun, K., Chen, G., Peng, H., Fang, H., Zhou, J., Li, J., Chen, S., & Zheng, H. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7458 · Cited by 26
Zhang, Y., Arnatt, C. K., Zhang, F., Wang, J., Haney, K. M., & Fang, X. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.127 · Cited by 24
Oncogenic Linear Collagen VI of Invasive Breast Cancer Is Induced by CCL5
Brett, E. A., Sauter, M. A., Timmins, É. M., Azimzadeh, O., Rosemann, M., Merl‐Pham, J., Hauck, S. M., Nelson, P. J., Becker, K., Schunn, I., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040991 · Cited by 24
C‑C motif chemokine receptors in gastric cancer (Review)
Ryu, H., Baek, S. W., Moon, J., Jo, I., Kim, N., & Lee, H. J. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1470 · Cited by 23
Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV
Gavegnano, C., Savarino, A., Owanikoko, T., & Marconi, V. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02267 · Cited by 22
Drug-Induced Resistance in Micrometastases: Analysis of Spatio-Temporal Cell Lineages
Pérez-Velázquez, J., & Rejniak, K. A. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00319 · Cited by 21
Zhang, F., Arnatt, C. K., Haney, K. M., Fang, H. C., Bajacan, J. E., Richardson, A. C., Ware, J. L., & Zhang, Y. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.07.049 · Cited by 20
Okita, K., Furuhata, T., Kimura, Y., Kawakami, M., Yamaguchi, K., Tsuruma, T., Zembutsu, H., & Hirata, K. (2005) · PubMed · Cited by 19
Bankov, K., Döring, C., Ustaszewski, A., Giefing, M., Herling, M., Cencioni, C., Spallotta, F., Gaetano, C., Küppers, R., Hansmann, M., et al. (2019) · Cancers · doi:10.3390/cancers11111687 · Cited by 18
Colombatti, M., Grasso, S., Porzia, A., Fracasso, G., Scupoli, M. T., Cingarlini, S., Poffe, O., Naim, H. Y., Heine, M., Tridente, G., et al. (2009) · PLoS ONE · doi:10.1371/annotation/f290f38a-4f71-43ad-b988-9f8d5a7329fe · Cited by 11
Smeets, A., Brouwers, B. A. H., Hatse, S., Laenen, A., Paridaens, R., Floris, G., Wildiers, H. P. M. W., & Christiaens, M.-R. (2013) · ISRN Immunology · doi:10.1155/2013/453561 · Cited by 10
Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond
Aldinucci, D., Pinto, A., Gloghini, A., & Carbone, A. (2010) · Blood · doi:10.1182/blood-2009-10-247809 · Cited by 10
Self-citationKulmann‐Leal, B., Ellwanger, J. H., & Chies, J. A. B. (2019) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2019.10.001 · Cited by 10
Blockade of CCR5 in melanoma: An alternative immune checkpoint modulator
Brehm, J. E., & Bedogni, B. (2019) · Experimental Dermatology · doi:10.1111/exd.14065 · Cited by 6
Butrym, A. K., Kryczek, I., Dłubek, D., Jaskuła, E., Lange, A., Jurczyszyn, A. J., & Mazur, G. J. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.01.006 · Cited by 5
Cited by
Stem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Clinical relevance of tumour-associated macrophages
Pittet, M. J., Michielin, O., & Migliorini, D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00620-6 · Cited by 731
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Macrophages at the interface of the co-evolving cancer ecosystem
Kloosterman, D. J., & Akkari, L. (2023) · Cell · doi:10.1016/j.cell.2023.02.020 · Cited by 427
Metadata
- Authors
- Aldinucci, D., Borghese, C., & Casagrande, N.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-07-02
- Volume
- 12
- Issue
- 7
- Pages
- 1765
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3039069304
- Cited by
- 400
- References
- 182
- FWCI
- 15.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.